alexa A New Platform For Sustained Topical Delivery Of Antiglaucoma Drugs
ISSN: 2155-9570

Journal of Clinical & Experimental Ophthalmology
Open Access

Like us on:
OMICS International organises 3000+ Global Conferenceseries Events every year across USA, Europe & Asia with support from 1000 more scientific Societies and Publishes 700+ Open Access Journals which contains over 50000 eminent personalities, reputed scientists as editorial board members.

Open Access Journals gaining more Readers and Citations

700 Journals and 15,000,000 Readers Each Journal is getting 25,000+ Readers

This Readership is 10 times more when compared to other Subscription Journals (Source: Google Analytics)

Share This Page

Additional Info

Loading Please wait..

4th International Conference on Clinical & Experimental Ophthalmology
July 14-16, 2014 DoubleTree by Hilton Baltimore-BWI Airport, USA

Hu Yang
ScientificTracks Abstracts: J Clin Exp Ophthalmol
DOI: 10.4172/2155-9570.S1.017
Glaucoma is a leading cause of blindness in the world. Glaucoma therapy typically begins with topical medications. Unfortunately, antiglaucoma drugs in form of eye drops are topically administered 1-3 times daily. This need for frequent dosing with multiple medications makes compliance difficult. Longer-acting formulations and combinations which require less frequent administration might improve compliance and therefore medication effectiveness. Recently, we developed a novel ocular drug delivery system, namely hybrid dendrimer hydrogel/poly (lactic-co-glycolic acid)(PLGA) nanoparticle platform (HDNP), for delivering antiglaucoma drugs topically. This platform is designed to deliver glaucoma drugs to the eye efficiently and release the drug in a slow fashion. Furthermore, this delivery platform is designed to be compatible with many of the glaucoma drugs that are currently approved for use. In this presentation, we will discuss this new delivery system with an emphasis on its structural features, properties, and pre-clinical results in glaucoma treatment. In addition, new chemistries developed to address effectiveness and safety of the dendrimer-based formulationswill be discussed.
Hu Yang is an Associate Professor in the Department of Biomedical Engineering at Virginia Commonwealth University. He has completed his Ph.D. from University of Akron in 2004 and conducted postdoctoral studies from University of Wisconsin-Madison School of Pharmacy. His research interests include dendrimer-based drug and gene delivery, nanomedicine, and novel polymers for pharmaceutical applications. He has won NSF CAREER Award and Wallace H. Coulter Translational Research Award.
image PDF   |   image HTML
Peer Reviewed Journals
Make the best use of Scientific Research and information from our 700 + peer reviewed, Open Access Journals
International Conferences 2017-18
Meet Inspiring Speakers and Experts at our 3000+ Global Annual Meetings

Contact Us

© 2008-2017 OMICS International - Open Access Publisher. Best viewed in Mozilla Firefox | Google Chrome | Above IE 7.0 version